Evidence map›Paper›PMID 40718791›Full record

ArticleFrontiers in molecular biosciences2025

Integrated network pharmacology and

Changying Jing, Yaqi Sun, Hongsheng Bi, Junguo Guo, Cong Ren, Jike Song, Beibei Wang, Qingmei Tian, Dadong Guo, Pengjuan He and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Changying JingShandong Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases, Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases in Universities of Shandong, Shandong Academy of Eye Disease Prevention and Therapy, Jinan, China.
Yaqi SunMedizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany.
Hongsheng BiShandong Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases, Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases in Universities of Shandong, Shandong Academy of Eye Disease Prevention and Therapy, Jinan, China.
Junguo GuoShandong Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases, Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases in Universities of Shandong, Shandong Academy of Eye Disease Prevention and Therapy, Jinan, China.
Cong RenShandong Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases, Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases in Universities of Shandong, Shandong Academy of Eye Disease Prevention and Therapy, Jinan, China.
Jike SongShandong Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases, Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases in Universities of Shandong, Shandong Academy of Eye Disease Prevention and Therapy, Jinan, China.
Beibei WangShandong Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases, Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases in Universities of Shandong, Shandong Academy of Eye Disease Prevention and Therapy, Jinan, China.
Qingmei TianShandong Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases, Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases in Universities of Shandong, Shandong Academy of Eye Disease Prevention and Therapy, Jinan, China.
Dadong GuoShandong Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases, Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases in Universities of Shandong, Shandong Academy of Eye Disease Prevention and Therapy, Jinan, China.
Pengjuan HeDepartment of Obstetrics and Gynecology, Maternal and Child Health hospotal of Shandong Province, Jinan, Shandong, China.
Lijie LiEndocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong, China.
Xiaofeng XieShandong Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases, Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases in Universities of Shandong, Shandong Academy of Eye Disease Prevention and Therapy, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Uveitis is a complex intraocular inflammatory disease and pathology results from the continuous production of proinflammatory cytokines in the optical axis. Qinghuo Rougan Formula (QHRGF), a traditional Chinese medicine (TCM) is now used to treat uveitis with desirable effect. However, the mechanism of action is still unclear. This study aimed to explore the potential diagnostic and therapeutic biomarkers for uveitis using systems biology methods, including network pharmacology and weighted gene co-expression network analysis (WGCNA). Methods: A molecular drug-compound-target-uveitis interaction network was established using network pharmacology. Functional enrichment analyses were performed to screen potential signaling pathways. The uveitis gene expression dataset from the Gene Expression Omnibus database was subjected to WGCNA to identify gene co-expression modules related to uveitis and explore the potential hub genes. The least absolute shrinkage and selection operator (LASSO) model was used to identify the hub genes. Additionally, molecular docking was performed to verify the accuracy and stability of the model. Finally, the suppressive effects of QHRGF on uveitis were experimentally verified Results: Network pharmacology and functional enrichment analysis showed that 18 targets and immune/inflammation-related pathways were associated with the QHRGF-targeted pathway network. The yellow module contained 120 genes had a strong correlation with uveitis using WGCNA. In total, 12 putative targets of QHRGF, differentially expressed genes, and yellow module genes were determined. Six hub genes were identified using LASSO model and the receiving operating characteristic curve analysis demonstrated the model can serve as biomarkers for uveitis. The advantages of these genes were approved using molecular docking. Finally, Conclusion: In conclusion, this research revealed that QHRGF can be used to treat uveitis through multiple components and targets. Meanwhile, the potential anti-inflammatory action of QHRGF in the treatment of uveitis was verified by combining network pharmacology and

Indexed as

network pharmacologyQinghuo Rougan Formulasystems biologyuveitisWGCNA

Identifiers

PMID40718791
PMCPMC12289509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.